Translational strategies for therapeutic development in nicotine addiction: Rethinking the conventional bench to bedside approach
Identifieur interne : 000C17 ( Main/Merge ); précédent : 000C16; suivant : 000C18Translational strategies for therapeutic development in nicotine addiction: Rethinking the conventional bench to bedside approach
Auteurs : Bernard Le Foll [Canada] ; Abhiram Pushparaj [Canada] ; Yaroslaw Pryslawsky [Canada] ; Benoit Forget [France] ; Kiran Vemuri [États-Unis] ; Alexandros Makriyannis [États-Unis] ; Jose M. Trigo [Canada]Source :
- Progress in neuro-psychopharmacology & biological psychiatry [ 0278-5846 ] ; 2013.
Abstract
Tobacco produces an impressive burden of disease resulting in premature death in half of users. Despite effective smoking cessation medications (nicotine replacement therapies, bupropion and varenicline), there is a very high rate of relapse following quit attempts. The use of efficient strategies for the development of novel treatments is a necessity. A `bench to bedside strategy' was initially used to develop cannabinoid CB1 receptor antagonists for the treatment of nicotine addiction. Unfortunately, after being tested on experimental animals, what seemed to be an interesting approach for the treatment of nicotine addiction resulted in serious unwanted side effects when tested in humans. Current research is focusing again on pre-clinical models in an effort to eliminate unwanted side effects while preserving the initially observed efficacy. A `bed side to bench strategy' was used to study the role of the insula (part of the frontal cortex) in nicotine addiction. This line of research started based on clinical observations that patients suffering stroke-induced lesions to the insula showed a greater likelihood to report immediate smoking cessation without craving or relapse. Subsequently, animal models of addiction are used to explore the role of insula in addiction. Due to the inherent limitations existing in clinical versus preclinical studies, the possibility of close interaction between both models seems to be critical for the successful development of novel therapeutic strategies for nicotine dependence.
Url:
DOI: 10.1016/j.pnpbp.2013.10.009
PubMed: 24140878
PubMed Central: 4002666
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000640
- to stream Pmc, to step Curation: 000637
- to stream Pmc, to step Checkpoint: 000429
- to stream Ncbi, to step Merge: 001237
- to stream Ncbi, to step Curation: 001237
- to stream Ncbi, to step Checkpoint: 001237
Links to Exploration step
PMC:4002666Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Translational strategies for therapeutic development in nicotine addiction: Rethinking the conventional bench to bedside approach</title>
<author><name sortKey="Foll, Bernard Le" sort="Foll, Bernard Le" uniqKey="Foll B" first="Bernard Le" last="Foll">Bernard Le Foll</name>
<affiliation wicri:level="1"><nlm:aff id="A1">Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, 33 Russell Street, Toronto, ON M5S 2S1, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, 33 Russell Street, Toronto, ON M5S 2S1</wicri:regionArea>
<wicri:noRegion>ON M5S 2S1</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="A2">Alcohol Research and Treatment Clinic, Addiction Medicine Services, Ambulatory Care and Structured Treatments, Centre for Addiction and Mental Health, Toronto, ON, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Alcohol Research and Treatment Clinic, Addiction Medicine Services, Ambulatory Care and Structured Treatments, Centre for Addiction and Mental Health, Toronto, ON</wicri:regionArea>
<wicri:noRegion>ON</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><nlm:aff id="A3">Department of Family and Community Medicine, University of Toronto, Toronto, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Family and Community Medicine, University of Toronto, Toronto</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
<affiliation wicri:level="4"><nlm:aff id="A4">Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Pharmacology and Toxicology, University of Toronto, Toronto</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
<affiliation wicri:level="4"><nlm:aff id="A5">Department of Psychiatry and Institute of Medical Sciences, University of Toronto, Toronto, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Psychiatry and Institute of Medical Sciences, University of Toronto, Toronto</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pushparaj, Abhiram" sort="Pushparaj, Abhiram" uniqKey="Pushparaj A" first="Abhiram" last="Pushparaj">Abhiram Pushparaj</name>
<affiliation wicri:level="1"><nlm:aff id="A1">Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, 33 Russell Street, Toronto, ON M5S 2S1, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, 33 Russell Street, Toronto, ON M5S 2S1</wicri:regionArea>
<wicri:noRegion>ON M5S 2S1</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pryslawsky, Yaroslaw" sort="Pryslawsky, Yaroslaw" uniqKey="Pryslawsky Y" first="Yaroslaw" last="Pryslawsky">Yaroslaw Pryslawsky</name>
<affiliation wicri:level="1"><nlm:aff id="A1">Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, 33 Russell Street, Toronto, ON M5S 2S1, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, 33 Russell Street, Toronto, ON M5S 2S1</wicri:regionArea>
<wicri:noRegion>ON M5S 2S1</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Forget, Benoit" sort="Forget, Benoit" uniqKey="Forget B" first="Benoit" last="Forget">Benoit Forget</name>
<affiliation wicri:level="3"><nlm:aff id="A6">Integrative Neurobiology of Cholinergic Systems, Department of Neuroscience, Pasteur Institute, 25 rue du Dr. Roux, Paris 75724, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Integrative Neurobiology of Cholinergic Systems, Department of Neuroscience, Pasteur Institute, 25 rue du Dr. Roux, Paris 75724</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Vemuri, Kiran" sort="Vemuri, Kiran" uniqKey="Vemuri K" first="Kiran" last="Vemuri">Kiran Vemuri</name>
<affiliation wicri:level="2"><nlm:aff id="A7">Center for Drug Discovery, Northeastern University, Boston, MA 02115-5005, United States</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Drug Discovery, Northeastern University, Boston, MA 02115-5005</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><nlm:aff id="A8">Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115-5005, United States</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115-5005</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><nlm:aff id="A9">Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115-5005, United States</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115-5005</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Makriyannis, Alexandros" sort="Makriyannis, Alexandros" uniqKey="Makriyannis A" first="Alexandros" last="Makriyannis">Alexandros Makriyannis</name>
<affiliation wicri:level="2"><nlm:aff id="A7">Center for Drug Discovery, Northeastern University, Boston, MA 02115-5005, United States</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Drug Discovery, Northeastern University, Boston, MA 02115-5005</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><nlm:aff id="A8">Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115-5005, United States</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115-5005</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><nlm:aff id="A9">Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115-5005, United States</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115-5005</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Trigo, Jose M" sort="Trigo, Jose M" uniqKey="Trigo J" first="Jose M." last="Trigo">Jose M. Trigo</name>
<affiliation wicri:level="1"><nlm:aff id="A1">Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, 33 Russell Street, Toronto, ON M5S 2S1, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, 33 Russell Street, Toronto, ON M5S 2S1</wicri:regionArea>
<wicri:noRegion>ON M5S 2S1</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">24140878</idno>
<idno type="pmc">4002666</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4002666</idno>
<idno type="RBID">PMC:4002666</idno>
<idno type="doi">10.1016/j.pnpbp.2013.10.009</idno>
<date when="2013">2013</date>
<idno type="wicri:Area/Pmc/Corpus">000640</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000640</idno>
<idno type="wicri:Area/Pmc/Curation">000637</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000637</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000429</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000429</idno>
<idno type="wicri:Area/Ncbi/Merge">001237</idno>
<idno type="wicri:Area/Ncbi/Curation">001237</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001237</idno>
<idno type="wicri:doubleKey">0278-5846:2013:Foll B:translational:strategies:for</idno>
<idno type="wicri:Area/Main/Merge">000C17</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Translational strategies for therapeutic development in nicotine addiction: Rethinking the conventional bench to bedside approach</title>
<author><name sortKey="Foll, Bernard Le" sort="Foll, Bernard Le" uniqKey="Foll B" first="Bernard Le" last="Foll">Bernard Le Foll</name>
<affiliation wicri:level="1"><nlm:aff id="A1">Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, 33 Russell Street, Toronto, ON M5S 2S1, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, 33 Russell Street, Toronto, ON M5S 2S1</wicri:regionArea>
<wicri:noRegion>ON M5S 2S1</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="A2">Alcohol Research and Treatment Clinic, Addiction Medicine Services, Ambulatory Care and Structured Treatments, Centre for Addiction and Mental Health, Toronto, ON, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Alcohol Research and Treatment Clinic, Addiction Medicine Services, Ambulatory Care and Structured Treatments, Centre for Addiction and Mental Health, Toronto, ON</wicri:regionArea>
<wicri:noRegion>ON</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><nlm:aff id="A3">Department of Family and Community Medicine, University of Toronto, Toronto, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Family and Community Medicine, University of Toronto, Toronto</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
<affiliation wicri:level="4"><nlm:aff id="A4">Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Pharmacology and Toxicology, University of Toronto, Toronto</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
<affiliation wicri:level="4"><nlm:aff id="A5">Department of Psychiatry and Institute of Medical Sciences, University of Toronto, Toronto, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Psychiatry and Institute of Medical Sciences, University of Toronto, Toronto</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pushparaj, Abhiram" sort="Pushparaj, Abhiram" uniqKey="Pushparaj A" first="Abhiram" last="Pushparaj">Abhiram Pushparaj</name>
<affiliation wicri:level="1"><nlm:aff id="A1">Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, 33 Russell Street, Toronto, ON M5S 2S1, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, 33 Russell Street, Toronto, ON M5S 2S1</wicri:regionArea>
<wicri:noRegion>ON M5S 2S1</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pryslawsky, Yaroslaw" sort="Pryslawsky, Yaroslaw" uniqKey="Pryslawsky Y" first="Yaroslaw" last="Pryslawsky">Yaroslaw Pryslawsky</name>
<affiliation wicri:level="1"><nlm:aff id="A1">Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, 33 Russell Street, Toronto, ON M5S 2S1, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, 33 Russell Street, Toronto, ON M5S 2S1</wicri:regionArea>
<wicri:noRegion>ON M5S 2S1</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Forget, Benoit" sort="Forget, Benoit" uniqKey="Forget B" first="Benoit" last="Forget">Benoit Forget</name>
<affiliation wicri:level="3"><nlm:aff id="A6">Integrative Neurobiology of Cholinergic Systems, Department of Neuroscience, Pasteur Institute, 25 rue du Dr. Roux, Paris 75724, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Integrative Neurobiology of Cholinergic Systems, Department of Neuroscience, Pasteur Institute, 25 rue du Dr. Roux, Paris 75724</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Vemuri, Kiran" sort="Vemuri, Kiran" uniqKey="Vemuri K" first="Kiran" last="Vemuri">Kiran Vemuri</name>
<affiliation wicri:level="2"><nlm:aff id="A7">Center for Drug Discovery, Northeastern University, Boston, MA 02115-5005, United States</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Drug Discovery, Northeastern University, Boston, MA 02115-5005</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><nlm:aff id="A8">Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115-5005, United States</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115-5005</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><nlm:aff id="A9">Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115-5005, United States</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115-5005</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Makriyannis, Alexandros" sort="Makriyannis, Alexandros" uniqKey="Makriyannis A" first="Alexandros" last="Makriyannis">Alexandros Makriyannis</name>
<affiliation wicri:level="2"><nlm:aff id="A7">Center for Drug Discovery, Northeastern University, Boston, MA 02115-5005, United States</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Drug Discovery, Northeastern University, Boston, MA 02115-5005</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><nlm:aff id="A8">Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115-5005, United States</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115-5005</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><nlm:aff id="A9">Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115-5005, United States</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115-5005</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Trigo, Jose M" sort="Trigo, Jose M" uniqKey="Trigo J" first="Jose M." last="Trigo">Jose M. Trigo</name>
<affiliation wicri:level="1"><nlm:aff id="A1">Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, 33 Russell Street, Toronto, ON M5S 2S1, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, 33 Russell Street, Toronto, ON M5S 2S1</wicri:regionArea>
<wicri:noRegion>ON M5S 2S1</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Progress in neuro-psychopharmacology & biological psychiatry</title>
<idno type="ISSN">0278-5846</idno>
<idno type="eISSN">1878-4216</idno>
<imprint><date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p id="P1">Tobacco produces an impressive burden of disease resulting in premature death in half of users. Despite effective smoking cessation medications (nicotine replacement therapies, bupropion and varenicline), there is a very high rate of relapse following quit attempts. The use of efficient strategies for the development of novel treatments is a necessity. A `bench to bedside strategy' was initially used to develop cannabinoid CB<sub>1</sub>
receptor antagonists for the treatment of nicotine addiction. Unfortunately, after being tested on experimental animals, what seemed to be an interesting approach for the treatment of nicotine addiction resulted in serious unwanted side effects when tested in humans. Current research is focusing again on pre-clinical models in an effort to eliminate unwanted side effects while preserving the initially observed efficacy. A `bed side to bench strategy' was used to study the role of the insula (part of the frontal cortex) in nicotine addiction. This line of research started based on clinical observations that patients suffering stroke-induced lesions to the insula showed a greater likelihood to report immediate smoking cessation without craving or relapse. Subsequently, animal models of addiction are used to explore the role of insula in addiction. Due to the inherent limitations existing in clinical versus preclinical studies, the possibility of close interaction between both models seems to be critical for the successful development of novel therapeutic strategies for nicotine dependence.</p>
</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C17 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 000C17 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= Main |étape= Merge |type= RBID |clé= PMC:4002666 |texte= Translational strategies for therapeutic development in nicotine addiction: Rethinking the conventional bench to bedside approach }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i -Sk "pubmed:24140878" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonFranceV1
This area was generated with Dilib version V0.6.29. |